Archives: Agenda

Trial Data in 2027: The Consent and Governance Layer Pharma Can’t Outsource to a CRO

  • What changes for sponsors when EHDS, eIDAS 2.0 wallets, the Data Governance Act and the AI Act converge on clinical trial data infrastructure.
  • Why current consent and audit-trail architectures will not survive a participant’s right to revoke or port their data, and what the Nordic region is already building as the working answer: consent evidence ledgers, privacy-preserving computation, and neutral data altruism intermediaries

Why Clinical Supply Teams Still Struggle to React in Real Time and How to Fix It

  • Understanding why delays still happen despite forecasting planning and risk mitigation strategies
  • Identifying gaps in real-time data visibility and decision-making across supply teams
  • Improving communication between sponsors vendors and sites to enable faster response
  • Building processes that allow supply to adapt quickly to changing trial conditions

LIVE DEBATE Balancing Cost Versus Quality in Clinical Supply And Making The Right Trade-Offs

  • Understanding where reducing cost versus protecting patient safety creates real tension in clinical supply
  • Exploring trade-offs between speed cost and quality versus operational risk and trial integrity
  • Debating when cost reduction is justified versus when it creates unacceptable risk
  • Defining where efficiency gains are possible versus where quality must remain non-negotiable